Scott J Fudemberg1, Corey Batiste, L Jay Katz. 1. Wills Eye Institute, Instructor, Jefferson Medical College Anna and William Goldberg Glaucoma Service and Research Center, 840 Walnut St. Ste 1130, Philadelphia, PA 19107, USA. sfudemberg@willseye.org
Abstract
BACKGROUND: The use of brimonidine to lower intraocular pressure has been the subject of considerable investigation. Variations of the initially approved drug including agents of a lower concentration (Alphagan P 0.15 and 0.1%, Allergan, Inc., Irvine, CA, USA) and a fixed-combination mating brimonidine with timolol (Combigan, Allergan) evolved the marketing and application of this therapy. OBJECTIVE: We review available evidence regarding the efficacy and side effect profile of brimonidine as well as its role in glaucoma management. RESULTS/ CONCLUSION: Brimonidine is an important component of topical glaucoma treatment that is most limited by local ocular intolerance.
BACKGROUND: The use of brimonidine to lower intraocular pressure has been the subject of considerable investigation. Variations of the initially approved drug including agents of a lower concentration (Alphagan P 0.15 and 0.1%, Allergan, Inc., Irvine, CA, USA) and a fixed-combination mating brimonidine with timolol (Combigan, Allergan) evolved the marketing and application of this therapy. OBJECTIVE: We review available evidence regarding the efficacy and side effect profile of brimonidine as well as its role in glaucoma management. RESULTS/ CONCLUSION:Brimonidine is an important component of topical glaucoma treatment that is most limited by local ocular intolerance.
Authors: Alan R Katritzky; C Dennis Hall; Bahaa El-Dien M El-Gendy; Bogdan Draghici Journal: J Comput Aided Mol Des Date: 2010-05-20 Impact factor: 3.686
Authors: Mohammad Reza Razeghinejad; Masoumeh Masoumpour; Mohammad Hossein Eghbal; Jonathan S Myers; Marlene R Moster Journal: Iran J Med Sci Date: 2016-09
Authors: Mari Carmen Desco; Julio Cesar Molina Martín; Jorge Mataix-Boronat; Isabel Pascual-Camps; Elena Palacios-Pozo; Marisa Barón-García; David P Piñero; Amparo Navea-Tejerina Journal: Ther Adv Ophthalmol Date: 2021-10-05